Article Text

Download PDFPDF

OP015/#492 Further stratification of no specific molecular profile (NSMP/P53WT) endometrial carcinomas to refine prognosis and identify therapeutic opportunities
  1. E Thompson1,
  2. J Huvila2,
  3. D Chiu3,
  4. S Leung4,
  5. A Lum3,
  6. A Jamieson5,
  7. M Köbel6,
  8. M Plante7,
  9. S Scott8,
  10. S Salvador9,
  11. D Vicus10,
  12. L Helpman11,
  13. M Kinloch12,
  14. K Grondin13,
  15. J Irving14,
  16. A Talhouk15,
  17. D Huntsman3,
  18. S Kommoss16,
  19. C Gilks17 and
  20. J Mcalpine5
  1. 1Univeristy of British Columbia, Molecular Oncology, Vancouver, Canada
  2. 2University of Turku, Biomedicine, Turku, Finland
  3. 3Molecular Oncology, University of British Columbia, Vancouver, Canada
  4. 4University of British Columbia, Genetic Pathology Evaluation Centre, Vancouver, Canada
  5. 5University of British Columbia, Gynecologic Oncology, Vancouver, Canada
  6. 6University of Calgary, Department of Pathology and Laboratory Medicine, Calgary, Canada
  7. 7Hotel Dieu de Quebec, Gynecology Oncology, Quebec, Canada
  8. 8Dalhousie University, Obstetrics and Gynaecology, Halifax, Canada
  9. 9McGill University, Jewish General Hospital, Gynecology Oncology, Montreal, Canada
  10. 10Sunnybrook Health Sciences Centre, Gynecologic Oncology, Toronto, Canada
  11. 11McMaster University, Juravinski Cancer Center, Hamilton Health Sciences, Gynecologic Oncology, Hamilton, Canada
  12. 12University of Saskatchewan, Pathology and Laboratory Medicine, Saskatoon, Canada
  13. 13Université Laval, CHU de Québec, Pathology, Quebec City, Canada
  14. 14University of British Columbia, Royal Jubilee Hospital, Pathology and Laboratory Medicine, Victoria, Canada
  15. 15University of British Columbia, Obstetrics and Gynecology, Vancouver, Canada
  16. 16Tuebingen Women’s Hospital, Gynecologic Oncology, Tuebingen, Germany
  17. 17UBC, Vancouver General Hospital, Pathology and Laboratory Medicine, Vancouver, Canada


Objectives Molecular classification identifies >50% of endometrial cancers (ECs) as having ‘no specific molecular profile/NSMP’; without mismatch repair deficiency, p53 IHC abnormalities, or pathogenic POLE mutations. Clinical presentation and outcomes within NSMP ECs are diverse and optimal treatment unclear with new ESMO/ESTRO/ESP guidelines unchanged for this molecular subtype. Better biomarkers are needed to predict if and what adjuvant therapies are needed.

Methods We characterized the clinicopathological and molecular (IHC+NGS) profiles of 1047 NSMP ECs in women from population-based and institutional cohorts, testing for associations with treatment response and outcomes.

Results Key pathologic and molecular features associated with survival parameters (p<0.01) are tabulated below. 31% of NSMP ECs had CTNNB1 mutations, however, associations with outcomes (PFS) were observed only within Gr1/2 early-stage endometrioid ECs(p=0.03), or if restricted to ECs without substantial LVI or L1CAM overexpression (p< 0.005). TP53 mutations (with normal p53IHC) were discovered in 41 women with a trend (p=0.06) to worse survival. On multivariable analysis only grade (3vs.1/2) maintained significance. 8% of this cohort would be eligible for current molecular classification de-escalation trials. Treatment received did not impact survival within low-, intermediate-, or high-intermediate risk NSMP ECs. Within high-risk, the most favorable outcomes were observed in women who received pelvic radiation with no observed benefit of chemotherapy.

Abstract OP015/#492 Table 1

Conclusions Additional prognostic stratification of NSMP ECs can be achieved with both pathologic and molecular features. Further study within NSMP subgroups may identify conventional, hormonal or targeted therapies that are more effective.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.